NABOTA 200U

Overview
NABOTA® is a high-purity Botulinum Toxin Type A developed by Daewoong Pharmaceuticals. FDA-approved and supported by clinical trials, it provides reliable, temporary smoothing of moderate to severe dynamic wrinkles.

Composition

• Clostridium botulinum toxin type A: 200 U

• Human serum albumin: 0.5 mg

• Sodium chloride: 0.9 mg

Appearance & Reconstitution
Supplied as a white-to-light-yellow lyophilisate in a clear vial. Reconstitute with sterile, preservative-free 0.9% saline to achieve 4 U/0.1 mL (200 U/5 mL). Gently swirl; avoid agitation. Label with date/time and use within 24 hours.

Mechanism of Action
Inhibits acetylcholine release at neuromuscular junctions, causing localized muscle relaxation to soften expression lines and relieve muscle hyperactivity.

Indications

• Aesthetic: Temporary improvement of moderate to severe glabellar lines, forehead lines, crow’s feet, periorbital and perioral wrinkles.

• Therapeutic: Chronic migraine prevention, neurogenic detrusor overactivity (urinary incontinence), axillary hyperhidrosis.

Administration
Inject intramuscularly with a 30–33 G needle. Adjust dosage and injection sites based on individual anatomy and treatment goals. Typical retreatment interval: 3–6 months.

Storage & Shelf Life
Store unopened vials at 2–8 °C; do not freeze. Handle reconstituted product aseptically. Shelf life is 36 months from manufacture.

Safety & Precautions
For use by licensed professionals only. Inspect solution before use for particulates or discoloration. Contraindicated in patients with hypersensitivity to any ingredients. Common side effects include injection-site discomfort, localized weakness, and transient ptosis. Serious systemic effects are rare but require immediate medical attention.